The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma

Motofumi Kumazoe, Mika Takai, Shun Hiroi, Chieri Takeuchi, Mai Kadomatsu, Takashi Nojiri, Hiroaki Onda, Jaehoon Bae, Yuhui Huang, Kanako Takamatsu, Shuya Yamashita, Kenji Kangawa, Hirofumi Tachibana

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.

Original languageEnglish
Pages (from-to)10813-10823
Number of pages11
JournalJournal of Biological Chemistry
Volume292
Issue number26
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Neoplastic Stem Cells
Stem cells
Adenocarcinoma
Pyruvic Acid
Oxidoreductases
Recurrence
Peroxisome Proliferator-Activated Receptors
AMP-Activated Protein Kinases
Chemotherapy
Pancreatic Neoplasms
Knockout Mice
Liver
Antineoplastic Agents
Neoplasms
Phosphotransferases
Neoplasm Metastasis
Phenotype
Drug Therapy
Proteins
Experiments

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. / Kumazoe, Motofumi; Takai, Mika; Hiroi, Shun; Takeuchi, Chieri; Kadomatsu, Mai; Nojiri, Takashi; Onda, Hiroaki; Bae, Jaehoon; Huang, Yuhui; Takamatsu, Kanako; Yamashita, Shuya; Kangawa, Kenji; Tachibana, Hirofumi.

In: Journal of Biological Chemistry, Vol. 292, No. 26, 01.01.2017, p. 10813-10823.

Research output: Contribution to journalArticle

Kumazoe, M, Takai, M, Hiroi, S, Takeuchi, C, Kadomatsu, M, Nojiri, T, Onda, H, Bae, J, Huang, Y, Takamatsu, K, Yamashita, S, Kangawa, K & Tachibana, H 2017, 'The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma', Journal of Biological Chemistry, vol. 292, no. 26, pp. 10813-10823. https://doi.org/10.1074/jbc.M116.772111
Kumazoe, Motofumi ; Takai, Mika ; Hiroi, Shun ; Takeuchi, Chieri ; Kadomatsu, Mai ; Nojiri, Takashi ; Onda, Hiroaki ; Bae, Jaehoon ; Huang, Yuhui ; Takamatsu, Kanako ; Yamashita, Shuya ; Kangawa, Kenji ; Tachibana, Hirofumi. / The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. In: Journal of Biological Chemistry. 2017 ; Vol. 292, No. 26. pp. 10813-10823.
@article{017750c0306f494d9c941f4be649a396,
title = "The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma",
abstract = "In 95{\%} of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.",
author = "Motofumi Kumazoe and Mika Takai and Shun Hiroi and Chieri Takeuchi and Mai Kadomatsu and Takashi Nojiri and Hiroaki Onda and Jaehoon Bae and Yuhui Huang and Kanako Takamatsu and Shuya Yamashita and Kenji Kangawa and Hirofumi Tachibana",
year = "2017",
month = "1",
day = "1",
doi = "10.1074/jbc.M116.772111",
language = "English",
volume = "292",
pages = "10813--10823",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "26",

}

TY - JOUR

T1 - The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma

AU - Kumazoe, Motofumi

AU - Takai, Mika

AU - Hiroi, Shun

AU - Takeuchi, Chieri

AU - Kadomatsu, Mai

AU - Nojiri, Takashi

AU - Onda, Hiroaki

AU - Bae, Jaehoon

AU - Huang, Yuhui

AU - Takamatsu, Kanako

AU - Yamashita, Shuya

AU - Kangawa, Kenji

AU - Tachibana, Hirofumi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.

AB - In 95% of patients with pancreatic ductal adenocarcinoma, recurrence is observed following chemotherapy. Findings from several studies have indicated that cancer stem cells (CSCs) are resistant to anticancer agents and may be involved in cancer recurrence and metastasis. The CD44 protein is a major CSC marker, and CD44 also plays an indispensable role in the CSC properties in several cancers, including pancreatic cancer; however, no clinical approach exists to inhibit CD44 activity. Here, we have performed knock-in/knockdown experiments, and we demonstrate that the forkhead box O3 (FOXO3)/liver kinase B1 (LKB1)/AMP-activated protein kinase/peroxisome proliferator-activated receptor-γ co-activator-1β (PGC-1β)/pyruvate dehydrogenase-A1 pathway is essential for CD44 expression and CSC properties. We observed that patients exhibiting high pyruvate dehydrogenase-A1 expression have a poor prognosis. Systemic PGC-1β knock-out mice are fertile and viable and do not exhibit an overt phenotype under normal conditions. This suggests that cGMP induction and PGC-1β inhibition represent potential strategies for treating patients with pancreatic ductal adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85021682258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021682258&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.772111

DO - 10.1074/jbc.M116.772111

M3 - Article

C2 - 28507102

AN - SCOPUS:85021682258

VL - 292

SP - 10813

EP - 10823

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 26

ER -